Cryoport Inc CYRX

$19.10 +3.05 (19.00%)

Valuation

Market cap
967,396,000
Revenue TTM
$176,180,000
Net income TTM
$78,300,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
44.44%
Debt to equity
0.38

Trading

Volume
2,586,100
Avg volume
837,888
Day's range
$17.17 – $19.53
Shares out
50,649,000
Stochastic %K
89%
Beta
1.89
Analysts
Strong Buy
Price target
$21.44

Price

Company profile

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic d...

Show more

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The company's products include Cryoport Express Shippers; Cryoport Elite; Cryoport Express Cryogenic HV3 Shipping System; Smartpak Condition Monitoring System and Tec4Med, an IoT-based monitoring solutions; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services; MVE Fusion cryogenic system, a self-sustaining cryogenic freezer; and MVE Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.

Industry
Integrated Freight & Logistics
Sector
Industrials
Phone
949 470 2300
Website
https://www.cryoportinc.com
Address
112 Westwood Place, Suite 350, Brentwood, United States

Latest news

Stocktwits

GTA_Terminal Nov 8, 11:25 PM
Dark pool check on $CYRX: what traded off the exchanges in the latest session. That came on a day the stock jumped hard, so the question is whether big holders were chasing it or selling into it. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=CYRX&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=CYRX Read the full article for the full details: https://globaltradersacademy.com/articles/cryoport-cyrx-technical-levels-options-flow-dark-pools-line-up-above-17-40?utm_source=stocktwits&utm_medium=social
0 replies
medguy Nov 6, 2:50 PM 0 replies
flychicken1991 Nov 5, 10:18 PM
$CYRX Cryoport Reports Third Quarter 2026 Financial Results. Impact: Positive (80%). Higher revenue guidance and positive adjusted EBITDA create upward pressure on CYRX's valuation by supporting expected sales and progress toward profitability; lower gross margin limits that support. Source and what to watch next: https://nimpact.tech/newsimpact/news/81e86f6e92025a9c/cyrx-cryoport-reports-third-quarter-2026-financial-results?utm_source=stocktwits&utm_medium=story_url
0 replies
jaykza Nov 5, 9:56 PM
$CYRX Great report. Look at growth in Phase 3 and Commercial. Raised guidance above prior high of prior raised guidance. New commercial therapy supported (Replimune's TUDRIQEV) can have up to 8 doses per treated patient, all requiring cryo storage and shipping. Still so early in the S-Curve here.
0 replies
StocktwitsEarnings Nov 5, 9:38 PM
$CYRX Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.25 down -92.31% YoY • Reported revenue of $50.22M up 13.54% YoY • Cryoport is increasing full-year 2026 revenue guidance to $197M to $199M; guidance depends on current business and expectations and may be impacted by external factors.
0 replies
1DayAtAtime63 Oct 14, 9:23 PM
$CYRX BTIG Research raises price target on CYRX to $26.00
0 replies
DueDilly102 Oct 5, 6:48 PM
$CYRX Breakout! Awesome!!! Come on 20!
1 replies
Yassine727 Oct 4, 10:40 PM
$DHT already on the move, $CYRX about to..
0 replies